TWA
MACK

TCI Wealth Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

TCI Wealth Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-127
Closed -$1K – 1479
2017
Q3 		$1K Hold
127
– – ﹤0.01% 1304
2017
Q2 		$1K Hold
127
– – ﹤0.01% 1314
2017
Q1 		$3K Buy
127
+63
+98% +$1.58K ﹤0.01% 890
2016
Q4 		$2K Hold
64
– – ﹤0.01% 1093
2016
Q3 		$3K Hold
64
– – ﹤0.01% 920
2016
Q2 		$3K Hold
64
– – ﹤0.01% 882
2016
Q1 		$4K Buy
64
+26
+68% +$1.36K ﹤0.01% 812
2015
Q4 		$2K Buy
+38
New +$2.67K ﹤0.01% 906

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCI Wealth Advisors's MACK Position: Q4 2017 in Review

TCI Wealth Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2017, closing a stake of 127 shares — an estimated $1K sold.

TCI Wealth Advisors first reported a position in MACK in Q4 2015 and held it in 8 quarters. The position peaked at $4K in Q1 2016. 78 funds tracked by Wall St. Rank hold MACK as of Q4 2017.

  • TCI Wealth Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • TCI Wealth Advisors sold 127 Merrimack Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1K.
  • TCI Wealth Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 8 quarters.
  • TCI Wealth Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $4K in Q1 2016.
  • 78 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2017.

Based on TCI Wealth Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.